Innovative medicines

Thursday, 29.09.2016 | 17:00 - 19:30 | Room

Organised by Main Association of Austrian Social Security Institutions, Belgian National Institute for Health and Disability Insurance (NIHDI) and Estonian Health Insurance Fund in cooperation with European Social Insurance Platform

The increasing tension between value, profit and accessibility

Modern, innovative pharmaceuticals often bring relevant improvements for the patients but the costs in most cases are exorbitant. This creates financial difficulties for health systems even in rich countries and excludes people from access to necessary treatments.

The session will be run as an interactive debate between the panel of experts and the audience and will build on the key challenges presented by the keynote speakers. The debate will be prompted by ‘multiple choice’ questions via E-voting-tool.

Keynote presentations – Reflection on the key challenges

Elias Mossialos, Professor of Health Policy, Department of Social Policy and Director of LSE Health, London School of Economics and Political Science

Els Torreele, Director, Access to Medicines and Innovation, Open Society Foundations (OSF)

Panel discussion and interactive debate

Richard Bergström, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Ri De Ridder, Director General, National Institute of Health and Disability Insurance (NIHDI)

Els Torreele, Director, Access to Medicines and Innovation, Open Society Foundations (OSF)

Karin Kadenbach, Member of the European Parliament (S&D, Austria)


David Rose, Director, LACS Training


EHFG News & Updates

EHFG Headquarters

EHFG Vienna Office

VAT No. ATU44155007 Bank Data:
IBAN AT 152040400200222240 
Bank Salzburger Sparkasse
Kurgartenstraße, 5630 Bad Hofgastein, Austria